| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 9 | 2023 | 82 | 3.520 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 63 | 3.440 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2022 | 51 | 2.690 |
Why?
|
| Imidazoles | 7 | 2019 | 55 | 2.600 |
Why?
|
| Piperazines | 7 | 2019 | 80 | 2.560 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2023 | 244 | 2.560 |
Why?
|
| Receptors, Estrogen | 6 | 2022 | 61 | 2.490 |
Why?
|
| Autophagy | 8 | 2022 | 30 | 2.300 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 190 | 2.260 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 414 | 1.860 |
Why?
|
| Cell Line, Tumor | 19 | 2024 | 251 | 1.850 |
Why?
|
| Tamoxifen | 4 | 2022 | 29 | 1.770 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 555 | 1.720 |
Why?
|
| Cisplatin | 5 | 2022 | 53 | 1.440 |
Why?
|
| Apoptosis | 9 | 2019 | 205 | 1.230 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2024 | 17 | 1.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 113 | 1.070 |
Why?
|
| Carboxypeptidases | 3 | 2022 | 6 | 1.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 3 | 2022 | 6 | 1.020 |
Why?
|
| Neoplasms | 2 | 2018 | 241 | 1.000 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 4 | 0.920 |
Why?
|
| Glycolysis | 3 | 2018 | 10 | 0.820 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2022 | 2 | 0.790 |
Why?
|
| Signal Transduction | 8 | 2022 | 451 | 0.770 |
Why?
|
| Fatty Acids | 1 | 2021 | 41 | 0.750 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 206 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-vav | 3 | 2010 | 5 | 0.710 |
Why?
|
| Humans | 37 | 2024 | 28413 | 0.680 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 44 | 0.640 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2020 | 15 | 0.640 |
Why?
|
| ErbB Receptors | 3 | 2010 | 55 | 0.630 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2018 | 2 | 0.630 |
Why?
|
| Ketoglutaric Acids | 1 | 2018 | 2 | 0.630 |
Why?
|
| Sp1 Transcription Factor | 1 | 2018 | 5 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 5 | 2010 | 12 | 0.610 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2007 | 30 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 4 | 2019 | 30 | 0.570 |
Why?
|
| Cell Lineage | 1 | 2015 | 25 | 0.510 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 50 | 0.470 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 28 | 0.460 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 13 | 0.460 |
Why?
|
| Sirolimus | 1 | 2014 | 20 | 0.460 |
Why?
|
| Nitric Oxide | 1 | 2014 | 81 | 0.450 |
Why?
|
| Protein Kinases | 1 | 2014 | 13 | 0.450 |
Why?
|
| Mice | 12 | 2022 | 1475 | 0.440 |
Why?
|
| Enzyme Activation | 6 | 2014 | 121 | 0.440 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 35 | 0.440 |
Why?
|
| MCF-7 Cells | 3 | 2021 | 13 | 0.440 |
Why?
|
| cdc42 GTP-Binding Protein | 2 | 2010 | 7 | 0.430 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2010 | 14 | 0.420 |
Why?
|
| Mammary Glands, Human | 2 | 2009 | 7 | 0.420 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2009 | 9 | 0.420 |
Why?
|
| Animals | 16 | 2022 | 3808 | 0.410 |
Why?
|
| Receptors, Glycine | 2 | 2009 | 2 | 0.410 |
Why?
|
| Paclitaxel | 2 | 2022 | 44 | 0.400 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 79 | 0.390 |
Why?
|
| Cytotoxins | 1 | 2010 | 2 | 0.360 |
Why?
|
| Epithelial Cells | 2 | 2010 | 81 | 0.360 |
Why?
|
| Adherens Junctions | 1 | 2010 | 4 | 0.360 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 53 | 0.360 |
Why?
|
| Cell Movement | 1 | 2010 | 82 | 0.350 |
Why?
|
| Cell Proliferation | 1 | 2010 | 181 | 0.340 |
Why?
|
| Morphogenesis | 1 | 2009 | 8 | 0.340 |
Why?
|
| Methylation | 2 | 2019 | 7 | 0.330 |
Why?
|
| Osteosarcoma | 3 | 2018 | 37 | 0.320 |
Why?
|
| Histones | 2 | 2019 | 28 | 0.320 |
Why?
|
| Caffeine | 1 | 2009 | 58 | 0.320 |
Why?
|
| Cell Survival | 4 | 2019 | 119 | 0.320 |
Why?
|
| Ubiquitin | 5 | 2007 | 31 | 0.320 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2022 | 5 | 0.310 |
Why?
|
| Kidney | 1 | 2009 | 174 | 0.300 |
Why?
|
| Bone Neoplasms | 3 | 2018 | 121 | 0.290 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2018 | 10 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 18 | 0.280 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2019 | 5 | 0.280 |
Why?
|
| Phosphorylation | 6 | 2016 | 150 | 0.270 |
Why?
|
| RNA Interference | 2 | 2019 | 36 | 0.270 |
Why?
|
| Retroviridae Proteins, Oncogenic | 2 | 2003 | 2 | 0.270 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2005 | 17 | 0.270 |
Why?
|
| Female | 11 | 2024 | 15762 | 0.270 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 45 | 0.270 |
Why?
|
| Cell Line | 6 | 2013 | 281 | 0.270 |
Why?
|
| Mitochondria | 2 | 2005 | 71 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 8 | 0.240 |
Why?
|
| Nitrogen | 1 | 2004 | 4 | 0.240 |
Why?
|
| Soil | 1 | 2004 | 6 | 0.240 |
Why?
|
| Receptors, Antigen | 1 | 2004 | 1 | 0.230 |
Why?
|
| Oxygen | 2 | 2015 | 81 | 0.230 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2024 | 2 | 0.230 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 202 | 0.230 |
Why?
|
| Trastuzumab | 2 | 2022 | 27 | 0.230 |
Why?
|
| Interleukin-6 | 1 | 2024 | 79 | 0.230 |
Why?
|
| Histone Deacetylase 1 | 1 | 2023 | 3 | 0.220 |
Why?
|
| Retinoblastoma Protein | 1 | 2023 | 11 | 0.220 |
Why?
|
| Benzamides | 1 | 2023 | 15 | 0.220 |
Why?
|
| Lysosomes | 1 | 2003 | 26 | 0.210 |
Why?
|
| Histone Demethylases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Lysine | 1 | 2022 | 15 | 0.210 |
Why?
|
| Mitochondrial Swelling | 1 | 2002 | 1 | 0.210 |
Why?
|
| Cadherins | 1 | 2022 | 36 | 0.210 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 15 | 0.210 |
Why?
|
| CD27 Ligand | 1 | 2022 | 2 | 0.210 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2022 | 3 | 0.210 |
Why?
|
| Antigens, CD | 1 | 2022 | 53 | 0.210 |
Why?
|
| Nanoparticles | 1 | 2022 | 11 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 17 | 0.200 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 2 | 0.200 |
Why?
|
| Aurora Kinase A | 1 | 2022 | 3 | 0.200 |
Why?
|
| Glioblastoma | 1 | 2022 | 9 | 0.200 |
Why?
|
| Macrophages | 1 | 2002 | 109 | 0.200 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 65 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 89 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 3 | 2022 | 50 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 19 | 0.170 |
Why?
|
| Autophagy-Related Proteins | 1 | 2019 | 3 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 5 | 0.160 |
Why?
|
| A549 Cells | 1 | 2018 | 10 | 0.160 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 2 | 0.160 |
Why?
|
| Adenosine | 1 | 2018 | 8 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 20 | 0.150 |
Why?
|
| Mutation | 4 | 2010 | 349 | 0.150 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 13 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2009 | 32 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.140 |
Why?
|
| Phospholipase C gamma | 2 | 2007 | 8 | 0.140 |
Why?
|
| Epidermal Growth Factor | 2 | 2010 | 28 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 5 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 7 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 6 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 18 | 0.130 |
Why?
|
| Macrolides | 1 | 2015 | 5 | 0.130 |
Why?
|
| Caspase 8 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Superoxides | 1 | 2015 | 24 | 0.130 |
Why?
|
| Chloroquine | 1 | 2015 | 6 | 0.130 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 25 | 0.130 |
Why?
|
| Cellular Senescence | 1 | 2015 | 18 | 0.130 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 67 | 0.130 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 93 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2015 | 116 | 0.120 |
Why?
|
| Phagosomes | 1 | 2014 | 3 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 20 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 11 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2016 | 164 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 39 | 0.120 |
Why?
|
| DNA Primers | 1 | 2014 | 49 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 38 | 0.110 |
Why?
|
| Base Sequence | 1 | 2014 | 102 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 113 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 72 | 0.110 |
Why?
|
| Models, Biological | 1 | 2016 | 329 | 0.110 |
Why?
|
| DNA Damage | 1 | 2014 | 28 | 0.110 |
Why?
|
| Transfection | 3 | 2020 | 122 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 281 | 0.110 |
Why?
|
| Membrane Potentials | 2 | 2005 | 172 | 0.110 |
Why?
|
| Cell Adhesion | 2 | 2010 | 33 | 0.110 |
Why?
|
| Aniline Compounds | 1 | 2013 | 36 | 0.110 |
Why?
|
| Triazoles | 1 | 2013 | 29 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 350 | 0.100 |
Why?
|
| Triterpenes | 1 | 2011 | 1 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 3 | 0.090 |
Why?
|
| src-Family Kinases | 3 | 2007 | 7 | 0.090 |
Why?
|
| Ubiquitination | 1 | 2010 | 15 | 0.090 |
Why?
|
| Protein Transport | 1 | 2010 | 32 | 0.090 |
Why?
|
| Actins | 1 | 2010 | 35 | 0.090 |
Why?
|
| Cytoskeleton | 1 | 2010 | 38 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 152 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 191 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 16 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2020 | 25 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 244 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 25 | 0.080 |
Why?
|
| Urodela | 1 | 2008 | 1 | 0.080 |
Why?
|
| Retinal Ganglion Cells | 1 | 2008 | 2 | 0.080 |
Why?
|
| Neural Inhibition | 1 | 2008 | 8 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 25 | 0.080 |
Why?
|
| Glycine | 1 | 2008 | 12 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2013 | 304 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2022 | 24 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 5 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 24 | 0.070 |
Why?
|
| Oncogene Protein v-cbl | 2 | 2003 | 2 | 0.070 |
Why?
|
| Necrosis | 2 | 2005 | 26 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2008 | 539 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 4 | 0.060 |
Why?
|
| Plant Development | 1 | 2004 | 3 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2017 | 41 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2004 | 14 | 0.060 |
Why?
|
| China | 1 | 2004 | 52 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 16 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 136 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 6 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 11 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 36 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 25 | 0.050 |
Why?
|
| Endosomes | 1 | 2003 | 8 | 0.050 |
Why?
|
| Endocytosis | 1 | 2003 | 17 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2004 | 320 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 65 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2003 | 59 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2003 | 148 | 0.050 |
Why?
|
| Ionophores | 1 | 2002 | 2 | 0.050 |
Why?
|
| Calcimycin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Ruthenium Red | 1 | 2002 | 7 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 4 | 0.050 |
Why?
|
| Blood Bactericidal Activity | 1 | 2002 | 5 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2003 | 102 | 0.050 |
Why?
|
| Intracellular Membranes | 1 | 2002 | 21 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 26 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2002 | 24 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 14 | 0.050 |
Why?
|
| Permeability | 1 | 2002 | 119 | 0.050 |
Why?
|
| Gene Expression | 1 | 2003 | 204 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 2 | 0.050 |
Why?
|
| Genistein | 1 | 2022 | 4 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 107 | 0.050 |
Why?
|
| Protein Binding | 3 | 2007 | 132 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2013 | 40 | 0.040 |
Why?
|
| Luciferases | 2 | 2013 | 26 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 629 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 10 | 0.040 |
Why?
|
| Reproductive History | 1 | 2017 | 1 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 25 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 6 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 110 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 275 | 0.030 |
Why?
|
| Tyrosine | 2 | 2007 | 25 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2007 | 60 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 604 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 204 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 673 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 10 | 0.030 |
Why?
|
| Biological Availability | 1 | 2013 | 19 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2013 | 24 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 110 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 108 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 339 | 0.030 |
Why?
|
| Rats | 1 | 2013 | 678 | 0.020 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2011 | 1 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 7 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 5 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 16 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 31 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 28 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 45 | 0.020 |
Why?
|
| Male | 2 | 2020 | 15338 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 2102 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 2413 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 93 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 199 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Telomerase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2009 | 52 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 67 | 0.020 |
Why?
|
| Retina | 1 | 2008 | 8 | 0.020 |
Why?
|
| Ligands | 1 | 2007 | 40 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 6 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 74 | 0.020 |
Why?
|
| Laminin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 37 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 18 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 120 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 26 | 0.020 |
Why?
|
| Collagen | 1 | 2007 | 84 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 120 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2007 | 136 | 0.020 |
Why?
|
| Wound Healing | 1 | 2007 | 160 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2005 | 11 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 22 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2005 | 13 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2004 | 10 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 8146 | 0.010 |
Why?
|
| Vanadates | 1 | 2003 | 3 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2003 | 10 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 10 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 27 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 57 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 35 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 45 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 9308 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 229 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 1499 | 0.010 |
Why?
|